CLINICAL CASE OF USAGE OF SERELAXIN IN THE PATIENT WITH ACUTE DECOMPENSATED HEART FAILURE
https://doi.org/10.15829/1560-4071-2016-4-83-88
Abstract
Heart failure remains one of the main problems in contemporary cardiology, taken high frequency of hospitalizations due to acute decompensation, and worse prognosis for this category of patients. One of the drugs influencing prognosis is serelaxin (recombinant human relaxin-2). Experience of serelaxin usage as 48-hour infusion for patients with ADHF showed rapid positive influence of the drug on clinical signs and symptoms, target organ damage markers (BNP, creatinine), hemodynamics parameters (MPAP).
About the Authors
I. V. Zhirov
Myasnikov A. L. SRI of Cardiology, Russian Cardiological Research-andProduction Complex of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
S. N. Nasonova
Myasnikov A. L. SRI of Cardiology, Russian Cardiological Research-andProduction Complex of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
S. N. Tereshchenko
Myasnikov A. L. SRI of Cardiology, Russian Cardiological Research-andProduction Complex of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
O. A. Nikolaeva
Myasnikov A. L. SRI of Cardiology, Russian Cardiological Research-andProduction Complex of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
T. M. Uskach
Myasnikov A. L. SRI of Cardiology, Russian Cardiological Research-andProduction Complex of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol, 2008;52:428-34.
2. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007;50:768-77.
3. Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 2007;297:61-70.
4. Castrini AI, Carubelli V, Lazzarini V, et al. Serelaxin a novel treatment for acute heart failure. Expert Rev. Clin. Pharmacol. 2015;8(5):549-57.
5. Vorobyeva NM, Panchenko EP, Dobrovolsky AB, Titaev VE. Increase of D-dimer in patients with cardiovascular disease without thromboembolic complications: what is the reason and what should I do? Angiology and vascular surgery. 2010; 16(4): 34-41. Russian (Воробьева Н.М., Панченко Е.П., Добровольский А.Б., Титаева Е.В. Повышение Д-димера у больных сердечно-сосудистыми заболеваниями без тромбоэмболических осложнений: с чем это связано и что делать? Ангиология и сосудистая хирургия. 2010; 16(4): 34-41).
Supplementary files
|
1. рисунки | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(1MB)
|
Indexing metadata ▾ | |
Review
For citations:
Zhirov I.V., Nasonova S.N., Tereshchenko S.N., Nikolaeva O.A., Uskach T.M. CLINICAL CASE OF USAGE OF SERELAXIN IN THE PATIENT WITH ACUTE DECOMPENSATED HEART FAILURE. Russian Journal of Cardiology. 2016;(4):83-88. (In Russ.) https://doi.org/10.15829/1560-4071-2016-4-83-88
Views:
764
Email this article 